Gurnet Point Capital, a healthcare investment firm, and Novo Holdings A/S, a holding and investment company, have acquired Paratek Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for diseases and other public health threats.

The company’s product, Nuzyra, is a once-daily oral and intravenous antibiotic available in the U.S. for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). All outstanding shares of Paratek were acquired for approximately $462 million, including the assumption of debt.

“We look forward to drawing upon the extensive experience of both Gurnet Point and Novo Holdings to provide lifesaving, transformative therapies to patients,” states Evan Loh, chief executive officer at Paratek.